Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.74 |
| ▸ | MEN1 | O00255 | 6/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 7/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | XBP1 | P17861 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | MITF | O75030 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | ALPL | P05186 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1454119 | 0.88 | KMT2A (0.73) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL1455800 | 0.88 | KMT2A (0.73) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL1455196 | 0.88 | KMT2A (0.73) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL27942800 | 0.87 | KMT2A (0.72) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL1455286 | 0.87 | KMT2A (0.90) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL10388703 | 0.85 | KMT2A (0.70) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL12218210 | 0.85 | KMT2A (0.70) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL5390788 | 0.85 | KMT2A (0.69) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL3619864 | 0.84 | MAPT (0.61) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL6929407 | 0.82 | KMT2A (0.69) | KMT2AMEN1ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9468694-B2 | Fluorination process | GE HEALTHCARE LIMITED (GB) | 2016-10-18 | — | — | US | disclosed |
| US-9468694-B2 | Fluorination process | GE HEALTHCARE LIMITED (GB) | 2016-10-18 | — | — | US | disclosed |
| US-20150328344-A1 | Fluorination Process | GE HEALTHCARE AS (NO) | 2015-11-19 | — | — | US | disclosed |
| US-20150328344-A1 | Fluorination Process | GE HEALTHCARE AS (NO) | 2015-11-19 | — | — | US | disclosed |
| US-9126961-B2 | Fluorination process | GE HEALTHCARE LIMITED (GB) | 2015-09-08 | — | — | US | disclosed |
| US-9126961-B2 | Fluorination process | GE HEALTHCARE LIMITED (GB) | 2015-09-08 | — | — | US | disclosed |
| EP-1915330-B1 | FLUORINATION PROCESS OF ANILIDE DERIVATIVES AND BENZOTHIAZOLE FLUORINATE DERIVATIVES AS IN VIVO IMAGING AGENTS | GE HEALTHCARE LTD (GB) | 2014-12-10 | — | — | EP | disclosed |
| US-20130225829-A1 | FLUORINATION PROCESS | GE HEALTHCARE AS (NO) | 2013-08-29 | — | — | US | disclosed |
| US-20130225829-A1 | FLUORINATION PROCESS | GE HEALTHCARE AS (NO) | 2013-08-29 | — | — | US | disclosed |
| US-8410312-B2 | Fluorination process of anilide derivatives and benzothiazole fluorinate derivatives as in vivo imaging agents | GE HEALTHCARE LIMITED (GB) | 2013-04-02 | — | — | US | disclosed |
| US-8410312-B2 | Fluorination process of anilide derivatives and benzothiazole fluorinate derivatives as in vivo imaging agents | GE HEALTHCARE LIMITED (GB) | 2013-04-02 | — | — | US | disclosed |
| US-20100234611-A1 | Fluorination Process of Anilide Derivatives and Benzothiazole Fluorinate Derivatives as in VIVO Imaging Agents | GE HEALTHCARE LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| US-20100234611-A1 | Fluorination Process of Anilide Derivatives and Benzothiazole Fluorinate Derivatives as in VIVO Imaging Agents | GE HEALTHCARE LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| CN-101282920-A | Method for fluorination of anilide derivatives and benzothiazole fluorinated derivatives as in vivo imaging agents | GE HEALTHCARE LTD (GB) | 2008-10-08 | — | — | CN | disclosed |
| EP-1915330-A1 | FLUORINATION PROCESS OF ANILIDE DERIVATIVES AND BENZOTHIAZOLE FLUORINATE DERIVATIVES AS IN VIVO IMAGING AGENTS | GE Healthcare Limited (GB) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007020400-A1 | FLUORINATION PROCESS OF ANILIDE DERIVATIVES AND BENZOTHIAZOLE FLUORINATE DERIVATIVES AS IN VIVO IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328344-A1 | Fluorination Process | CYP2F1, C1R, C1S | KMT2A 1861/4885MEN1 46/4885ALDH1A1 1369/4885 |
| US-20100234611-A1 | Fluorination Process of Anilide Derivatives and Benzothiazole Fluorinate Derivatives as in VIVO Imaging Agents | Q6ZSR9, AFF1, F9 | KMT2A 1522/4885MEN1 69/4885ALDH1A1 382/4885 |
| US-20130225829-A1 | FLUORINATION PROCESS | CYP2F1, C1R, C1S | KMT2A 1861/4885MEN1 46/4885ALDH1A1 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.